Isomorphic Labs announces collaboration with Novartis
Isomorphic Labs →Isomorphic Labs announced a strategic research collaboration with Novartis focused on discovering small-molecule therapeutics against three undisclosed targets. The terms included a [figure hidden] upfront payment and funding of selected research costs. Isomorphic Labs was eligible for up to [figure hidden] in performance-based milestones, excluding the upfront payment, and tiered royalties on net sales. The milestone ceiling is contingent and does not establish earned revenue. The collaboration combined Isomorphic’s AI technology, including its work on next-generation AlphaFold, with Novartis’s medicinal chemistry and disease-area expertise. The companies described research and discovery work, rather than approval or commercialization of a specific therapeutic product.